Cargando…

Time to Develop and Predictors for Incidence of Tuberculosis among Children Receiving Antiretroviral Therapy

Infection by the human immune deficiency virus (HIV) is the strongest risk factor for latent or new infection of tuberculosis (TB) through reduction of CD4 T-lymphocytes and cellular immune function. Almost one-third of deaths among people living with HIV are attributed to tuberculosis. Despite this...

Descripción completa

Detalles Bibliográficos
Autores principales: Kebede, Fassikaw, Kebede, Tsehay, Kebede, Birhanu, Abate, Abebe, Jara, Dube, Negese, Belete, Shaweno, Tamrat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605917/
https://www.ncbi.nlm.nih.gov/pubmed/34812290
http://dx.doi.org/10.1155/2021/6686019
_version_ 1784602250887299072
author Kebede, Fassikaw
Kebede, Tsehay
Kebede, Birhanu
Abate, Abebe
Jara, Dube
Negese, Belete
Shaweno, Tamrat
author_facet Kebede, Fassikaw
Kebede, Tsehay
Kebede, Birhanu
Abate, Abebe
Jara, Dube
Negese, Belete
Shaweno, Tamrat
author_sort Kebede, Fassikaw
collection PubMed
description Infection by the human immune deficiency virus (HIV) is the strongest risk factor for latent or new infection of tuberculosis (TB) through reduction of CD4 T-lymphocytes and cellular immune function. Almost one-third of deaths among people living with HIV are attributed to tuberculosis. Despite this evidence, in Ethiopia, there is a scarcity of information regarding the incidence of tuberculosis for children living with HIV. Thus, this study assessed time to develop and predictors for incidence of tuberculosis in children attending HIV/AIDS care in public hospitals: North West Ethiopia 2021. Methods. A facility-based retrospective cohort study was conducted among 421 seropositive children on antiretroviral therapy in two hospitals between January 1, 2011 and December 31, 2020. EPI-DATA version 3.2 and STATA/14 software were used for data entry and analysis, respectively. Tuberculosis-free survival time was estimated using the Kaplan-Meier survival curve. Bivariate and multivariable Cox regression model was fitted to identify predictors at a P value <0.05 within 95% CI. Results. In the final analysis, a total of 421 seropositive children were included, of whom, 64 (15.2%) developed tuberculosis at the time of follow-up. The mean (±SD) age of the children was 10.62 ± 3.32 years, with a median (IQR) time to develop TB that was 23.5 (IQR = ±19) months. This study found that the incidence of tuberculosis was 5.9 (95% CI: 4.7; 7.6) per 100 person-years (PY) risk of observation. Cases at baseline not taking cotrimoxazol preventive therapy (CPT) (AHR = 2.5; 95% CI, 1.4-4.7, P < 0.021), being severely stunted (AHR = 2.9: 95% CI, 1.2-7.8, P < 0.03), and having low hemoglobin level (AHR = 4.0; 95% CI, 2.1-8.1, P < 0.001) were found to be predictors of tuberculosis. Conclusion. A higher rate of tuberculosis incidence was reported in our study as compared with previous studies in Ethiopia. Cases at baseline not taking cotrimoxazol preventive therapy (CPT), being severely stunted, and having low hemoglobin (≤10 mg/dl) levels were found to be at higher risk to developed TB incidence.
format Online
Article
Text
id pubmed-8605917
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-86059172021-11-21 Time to Develop and Predictors for Incidence of Tuberculosis among Children Receiving Antiretroviral Therapy Kebede, Fassikaw Kebede, Tsehay Kebede, Birhanu Abate, Abebe Jara, Dube Negese, Belete Shaweno, Tamrat Tuberc Res Treat Research Article Infection by the human immune deficiency virus (HIV) is the strongest risk factor for latent or new infection of tuberculosis (TB) through reduction of CD4 T-lymphocytes and cellular immune function. Almost one-third of deaths among people living with HIV are attributed to tuberculosis. Despite this evidence, in Ethiopia, there is a scarcity of information regarding the incidence of tuberculosis for children living with HIV. Thus, this study assessed time to develop and predictors for incidence of tuberculosis in children attending HIV/AIDS care in public hospitals: North West Ethiopia 2021. Methods. A facility-based retrospective cohort study was conducted among 421 seropositive children on antiretroviral therapy in two hospitals between January 1, 2011 and December 31, 2020. EPI-DATA version 3.2 and STATA/14 software were used for data entry and analysis, respectively. Tuberculosis-free survival time was estimated using the Kaplan-Meier survival curve. Bivariate and multivariable Cox regression model was fitted to identify predictors at a P value <0.05 within 95% CI. Results. In the final analysis, a total of 421 seropositive children were included, of whom, 64 (15.2%) developed tuberculosis at the time of follow-up. The mean (±SD) age of the children was 10.62 ± 3.32 years, with a median (IQR) time to develop TB that was 23.5 (IQR = ±19) months. This study found that the incidence of tuberculosis was 5.9 (95% CI: 4.7; 7.6) per 100 person-years (PY) risk of observation. Cases at baseline not taking cotrimoxazol preventive therapy (CPT) (AHR = 2.5; 95% CI, 1.4-4.7, P < 0.021), being severely stunted (AHR = 2.9: 95% CI, 1.2-7.8, P < 0.03), and having low hemoglobin level (AHR = 4.0; 95% CI, 2.1-8.1, P < 0.001) were found to be predictors of tuberculosis. Conclusion. A higher rate of tuberculosis incidence was reported in our study as compared with previous studies in Ethiopia. Cases at baseline not taking cotrimoxazol preventive therapy (CPT), being severely stunted, and having low hemoglobin (≤10 mg/dl) levels were found to be at higher risk to developed TB incidence. Hindawi 2021-11-13 /pmc/articles/PMC8605917/ /pubmed/34812290 http://dx.doi.org/10.1155/2021/6686019 Text en Copyright © 2021 Fassikaw Kebede et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kebede, Fassikaw
Kebede, Tsehay
Kebede, Birhanu
Abate, Abebe
Jara, Dube
Negese, Belete
Shaweno, Tamrat
Time to Develop and Predictors for Incidence of Tuberculosis among Children Receiving Antiretroviral Therapy
title Time to Develop and Predictors for Incidence of Tuberculosis among Children Receiving Antiretroviral Therapy
title_full Time to Develop and Predictors for Incidence of Tuberculosis among Children Receiving Antiretroviral Therapy
title_fullStr Time to Develop and Predictors for Incidence of Tuberculosis among Children Receiving Antiretroviral Therapy
title_full_unstemmed Time to Develop and Predictors for Incidence of Tuberculosis among Children Receiving Antiretroviral Therapy
title_short Time to Develop and Predictors for Incidence of Tuberculosis among Children Receiving Antiretroviral Therapy
title_sort time to develop and predictors for incidence of tuberculosis among children receiving antiretroviral therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605917/
https://www.ncbi.nlm.nih.gov/pubmed/34812290
http://dx.doi.org/10.1155/2021/6686019
work_keys_str_mv AT kebedefassikaw timetodevelopandpredictorsforincidenceoftuberculosisamongchildrenreceivingantiretroviraltherapy
AT kebedetsehay timetodevelopandpredictorsforincidenceoftuberculosisamongchildrenreceivingantiretroviraltherapy
AT kebedebirhanu timetodevelopandpredictorsforincidenceoftuberculosisamongchildrenreceivingantiretroviraltherapy
AT abateabebe timetodevelopandpredictorsforincidenceoftuberculosisamongchildrenreceivingantiretroviraltherapy
AT jaradube timetodevelopandpredictorsforincidenceoftuberculosisamongchildrenreceivingantiretroviraltherapy
AT negesebelete timetodevelopandpredictorsforincidenceoftuberculosisamongchildrenreceivingantiretroviraltherapy
AT shawenotamrat timetodevelopandpredictorsforincidenceoftuberculosisamongchildrenreceivingantiretroviraltherapy